查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1607784

合約研究組織服務市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型、應用、最終用戶、地區和競爭細分，2019-2029F

Contract Research Organization Services Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By End User, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023年全球合約研究組織（CRO）服務市值為812.3億美元，預計到2029年將達到1394.2億美元，預測期內複合年成長率為9.42%。

市場概況
預測期 2025-2029
2023 年市場規模 812.3億美元
2029 年市場規模 1394.2億美元
2024-2029 年複合年成長率 9.42%
成長最快的細分市場 臨床
最大的市場 北美洲

由於內部藥物開發流程的複雜性和成本不斷上升，全球合約研究組織 (CRO) 服務市場正在穩步成長。製藥和生技公司越來越依賴 CRO 外包其研發 (R&D) 活動，從而受益於專業知識和成本效率。憑藉強大的創新藥物和生物製劑產品線，對綜合臨床試驗和早期開發服務的需求不斷成長。

對精準醫療、個人化治療和罕見疾病研究的日益關注進一步放大了對專業 CRO 服務的需求。此外，人工智慧（AI）和機器學習的整合等技術進步正在提高臨床試驗流程的效率和準確性，推動市場擴張。

該市場的特點是新興趨勢，例如採用分散臨床試驗和納入真實世界證據（RWE）研究以改善試驗結果。結合了傳統方法和虛擬方法的混合試驗模型越來越被接受，反映了產業向以患者為中心的方法的演變。 CRO 也大力投資資料分析和基於人工智慧的工具，以最佳化試驗設計、加強患者招募並改善資料管理。這些創新符合對加速藥品核准流程日益成長的監管要求，使 CRO 成為製藥公司不可或缺的合作夥伴。不斷成長的生物製劑和生物相似藥領域以及細胞和基因療法領域充滿了機遇，這些領域需要複雜的研發和監管專業知識。

儘管成長前景巨大，但該市場仍面臨一些挑戰，包括各地區監管的複雜性以及臨床試驗中的倫理問題。鑑於利基治療領域對專業知識的高需求，招募和留住熟練的專業人員仍然是一個長期存在的問題。 CRO 之間的激烈競爭以及提供具有成本效益且高品質的服務的壓力進一步給該行業帶來壓力。資料隱私問題和敏感臨床資訊的安全處理也存在障礙，特別是隨著數位化在臨床研究中變得越來越普遍。應對這些挑戰，同時跟上技術進步的步伐，對於維持市場成長和確保可靠的服務交付至關重要。

主要市場促進因素

臨床試驗數量不斷增加

對具有成本效益的治療的需求不斷增加

醫藥研發支出不斷增加，藥品管道不斷增加

主要市場挑戰

競爭加劇和成本壓力

臨床試驗管理的複雜性

主要市場趨勢

更多採用去中心化和虛擬試驗

真實世界證據 (RWE) 和真實世界數據 (RWD) 整合

細分市場洞察

類型洞察

應用洞察

區域洞察

目錄

第 1 章：服務概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球合約研究組織 (CRO) 服務市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型（早期開發服務 [化學、製造和控制 (CMC)、臨床前服務和發現]、臨床 [第 1 階段、第 2 階段、第 3 階段和第 4 階段]、實驗室服務等）
    • 依應用（腫瘤學、神經病學、心臟病學、傳染病、代謝紊亂、腎臟/腎臟病學等）
    • 按最終用戶（製藥和生物技術公司、醫療器材公司、學術和研究機構等）
    • 按公司分類 (2023)
    • 按地區
  • 市場地圖

第 6 章：北美合約研究組織 (CRO) 服務市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 7 章：歐洲合約研究組織 (CRO) 服務市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太合約研究組織 (CRO) 服務市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第 9 章：南美洲合約研究組織 (CRO) 服務市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲合約研究組織 (CRO) 服務市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新動態

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • Medpace, Inc.
  • Laboratory Corporation of America Holdings
  • ICON plc
  • IQVIA Inc.
  • Syneos Health Inc.
  • Parexel International Corporation
  • Charles River Laboratories International Inc.
  • Thermofisher Scientific Inc.
  • Pharmaron Beijing Co., Ltd.
  • Altasciences

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 26754

Global Contract Research Organization (CRO) Services Market was valued at USD 81.23 Billion in 2023 and is expected to reach USD 139.42 Billion by 2029 with a CAGR of 9.42% during the forecast period.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 81.23 Billion
Market Size 2029USD 139.42 Billion
CAGR 2024-20299.42%
Fastest Growing SegmentClinical
Largest MarketNorth America

The Global Contract Research Organization (CRO) Services Market is witnessing steady growth driven by the rising complexity and costs associated with in-house drug development processes. Pharmaceutical and biotechnology companies increasingly rely on CROs to outsource their research and development (R&D) activities, benefiting from specialized expertise and cost efficiency. With a robust pipeline of innovative drugs and biologics, there is a growing demand for comprehensive clinical trials and early-phase development services.

The increasing focus on precision medicine, personalized therapies, and rare disease research has further amplified the demand for specialized CRO services. Moreover, advancements in technology, such as the integration of artificial intelligence (AI) and machine learning, are enhancing the efficiency and accuracy of clinical trial processes, driving market expansion.

The market is characterized by emerging trends such as the adoption of decentralized clinical trials and the incorporation of real-world evidence (RWE) studies to improve trial outcomes. The growing acceptance of hybrid trial models, which combine traditional and virtual methodologies, reflects the industry's evolution toward patient-centric approaches. CROs are also investing heavily in data analytics and AI-based tools to optimize trial designs, enhance patient recruitment, and improve data management. These innovations align with the increasing regulatory requirements for faster drug approval processes, making CROs indispensable partners for pharmaceutical companies. Opportunities abound in the growing biologics and biosimilar segments, as well as in cell and gene therapies, which demand sophisticated R&D and regulatory expertise.

Despite significant growth prospects, the market faces several challenges, including regulatory complexities across various regions and ethical concerns in clinical trials. Recruiting and retaining skilled professionals remain a persistent issue, given the high demand for expertise in niche therapeutic areas. Intense competition among CROs and the pressure to deliver cost-effective yet high-quality services further strain the industry. Data privacy concerns and the secure handling of sensitive clinical information also present hurdles, particularly as digitalization becomes more prevalent in clinical research. Addressing these challenges while keeping pace with technological advancements will be critical for sustaining market growth and ensuring reliable service delivery.

Key Market Drivers

Increasing Number of Clinical Trials

The increasing number of clinical trials is a significant driver for the global Contract Research Organization (CRO) services market. As the demand for new and innovative treatments for chronic, infectious, and rare diseases continues to rise, pharmaceutical and biotechnology companies are ramping up their research efforts. Clinical trials are essential for evaluating the safety, efficacy, and quality of new therapies, and their growing number reflects the expanding pipeline of drug candidates under development globally.

With advancements in biotechnology and genomics, personalized medicine is gaining prominence, leading to the development of targeted therapies. These therapies often require complex and specialized trial designs, which pharmaceutical companies increasingly outsource to CROs for expertise, infrastructure, and cost-efficiency. The growth of biologics, biosimilars, and gene and cell therapies has also contributed to the surge in clinical trials. These advanced therapeutic products necessitate sophisticated trial management capabilities, making CROs vital partners in navigating their complex regulatory and logistical requirements.

The shift toward multi-regional clinical trials, driven by the globalization of drug development, further increases the reliance on CROs. These organizations have the networks, experience, and capabilities to manage trials across diverse geographic locations. Hybrid and decentralized trial models, which enhance patient-centric approaches, have added complexity to trial execution, providing further impetus for CRO involvement.

As per the ClinicalTrials.gov, the global number of registered studies was 517,029 and total number of recruiting studies was 67,683 as of 25 November 2024. The clinical trials has been rising annually, driven by the increasing focus on unmet medical needs and the demand for innovative treatments. As the pharmaceutical and biotechnology industries continue to expand, the role of CROs in facilitating clinical trials is expected to grow, positioning them as indispensable contributors to the drug development process. This trend underscores the crucial role of CRO services in accelerating medical advancements and meeting global healthcare needs.

Increasing Demand for Cost-effective Treatment

The increasing demand for cost-effective treatment is one of the key drivers for the global Contract Research Organization (CRO) services market. As healthcare costs continue to rise globally, pharmaceutical and biotechnology companies are facing growing pressure to develop affordable treatments while ensuring high-quality standards. In response, these companies are increasingly outsourcing their research and development (R&D) activities to CROs, which provide cost-efficient solutions for managing clinical trials and regulatory requirements. By partnering with CROs, companies can reduce the operational costs associated with maintaining in-house research teams, facilities, and infrastructure.

Outsourcing to CROs also allows pharmaceutical companies to access specialized expertise in areas such as clinical trial design, patient recruitment, data management, and regulatory affairs. This expertise helps reduce the time and cost associated with clinical trials, making the drug development process more efficient. CROs offer flexible, scalable services that enable pharmaceutical companies to manage the complexities of modern drug development without the burden of fixed costs. These factors are especially crucial in an environment where cost-effectiveness is a priority for both the industry and regulatory agencies.

As the market for biologics, biosimilars, and personalized medicine expands, there is an increased need for efficient research processes to develop these advanced therapies. CROs are well-positioned to support the development of these complex drugs in a cost-effective manner, helping companies meet the growing demand for innovative treatments while keeping development costs under control. The trend toward more affordable, accessible healthcare options further underscores the need for CROs to offer tailored solutions that meet both regulatory requirements and budget constraints. This shift toward cost-effective treatment is expected to continue driving the demand for CRO services across the global market.

Rising pharmaceutical R&D expenditure and increasing drug pipeline

Rising pharmaceutical R&D expenditure and an increasing drug pipeline are pivotal drivers for the global Contract Research Organization (CRO) services market. The pharmaceutical and biotechnology industries are experiencing significant growth in their research and development investments to meet the demand for innovative treatments targeting chronic diseases, rare disorders, and emerging health threats. As companies allocate substantial budgets to R&D, they increasingly rely on CROs to optimize processes, manage costs, and accelerate timelines for drug discovery and development.

Expanding drug pipelines across therapeutic areas such as oncology, neurology, and infectious diseases have heightened the need for specialized expertise and infrastructure to manage complex clinical trials and regulatory compliance. Developing innovative therapies, including biologics, biosimilars, and gene therapies, has further intensified this demand. CROs offer end-to-end solutions, from early-phase discovery to late-phase clinical trials, providing pharmaceutical companies the flexibility to focus on core competencies while outsourcing labor-intensive tasks.

Data from industry reports indicate that global R&D spending by pharmaceutical companies has grown consistently, driven by an increasing number of drug approvals and an intensified focus on precision medicine. The surge in investment is also attributed to the rise in personalized and targeted therapies that require advanced methodologies and robust data analysis. CROs have become indispensable partners in this landscape, offering expertise in adaptive trial designs, real-world evidence studies, and patient recruitment strategies.

As competition among pharmaceutical companies intensifies, there is a growing urgency to bring innovative drugs to market efficiently. CROs play a critical role in enabling companies to streamline operations, ensure regulatory compliance, and enhance the scalability of their R&D efforts. This dynamic positions CROs as integral to the success of the pharmaceutical industry's growth strategies, supporting the continuous expansion of the drug development pipeline globally.

Key Market Challenges

Increasing Competition and Cost Pressures

Increasing competition and cost pressures are significant challenges for the global Contract Research Organization (CRO) services market. The CRO industry has witnessed rapid growth in recent years, leading to the entry of numerous players vying for contracts with pharmaceutical and biotechnology companies. As a result, the competition for both large-scale contracts and smaller, niche services have become fierce. This has created pricing pressures across the market, with CROs offering more competitive rates to win business. While this is beneficial for pharmaceutical companies, it places significant strain on CROs, particularly smaller and mid-sized organizations, as they struggle to maintain profitability.

The growing emphasis on cost efficiency within the pharmaceutical and biotech sectors is another challenge. As drug development costs rise, many companies are turning to CROs for affordable, scalable solutions to manage clinical trials and regulatory requirements. However, as CROs compete for business, the need to keep costs low can lead to challenges in maintaining service quality. Many CROs are forced to lower their service fees, which could impact their ability to invest in technology, talent, and innovation, crucial for keeping up with the increasing complexity of clinical trials.

Large, established CROs with extensive infrastructure, a wide range of services, and global reach have a competitive edge, further intensifying the pressure on smaller players. These larger firms can offer comprehensive, integrated solutions at a more competitive price point, while smaller CROs may struggle with limited resources. This has created an uneven playing field in the industry, where only the most resourceful and agile CROs can succeed amidst the increasing competition and cost pressures.

Complexity in Clinical Trial Management

Complexity in clinical trial management is one of the key challenges facing the global Contract Research Organization (CRO) services market. Clinical trials today are becoming increasingly complex due to the evolving nature of medical research, the rise of personalized medicine, and the growing focus on specialized treatments such as biologics, gene therapies, and precision medicine. These trials often require tailored designs, sophisticated methodologies, and specialized expertise, which adds significant complexity to their execution.

One of the primary factors contributing to this complexity is the growing demand for multi-center and multi-regional trials. With the globalization of drug development, managing trials across different geographical locations, while ensuring regulatory compliance, patient safety, and data consistency, becomes more challenging. Geographic diversity can introduce logistical issues such as language barriers, cultural differences in patient recruitment, and varying regulatory requirements, which can significantly delay the progress of trials and increase costs.

The adoption of advanced technologies, including decentralized clinical trials (DCTs) and digital platforms for remote monitoring and data collection, has added another layer of complexity. While these technologies offer numerous benefits, they also require CROs to manage a broader range of platforms and integrate data from multiple sources, which demands high levels of coordination and data security.

Moreover, the increasing involvement of regulatory agencies in trial oversight requires CROs to keep up with changing regulations across multiple jurisdictions, ensuring compliance with standards like Good Clinical Practice (GCP) and Good Laboratory Practice (GLP). Non-compliance or mismanagement of these intricate processes can lead to delays, data inaccuracies, and regulatory penalties.

As clinical trials become more intricate, CROs must invest in specialized capabilities and highly skilled personnel to navigate these challenges efficiently. These complexities in trial design, management, and regulatory adherence can significantly impact timelines, budgets, and the success of clinical trials, placing considerable pressure on CROs to meet client expectations.

Key Market Trends

Increased Adoption of Decentralized and Virtual Trials

The increased adoption of decentralized and virtual clinical trials is a prominent trend driving the global Contract Research Organization (CRO) services market. Decentralized trials (DCTs) use digital technologies to conduct clinical studies remotely, allowing patients to participate from home or local healthcare facilities. This shift is particularly appealing for studies involving chronic conditions, rare diseases, or diverse patient populations spread across vast geographies. Virtual trials enhance patient access and convenience, reduce trial costs, and improve patient retention rates.

The rise of telemedicine, wearable devices, and mobile health technologies has made decentralized trials more feasible, offering real-time data collection and monitoring without the need for patients to visit clinical sites. These innovations also address patient concerns related to travel, time commitment, and geographical barriers, which often deter participation in traditional trials. CROs are increasingly adopting DCT models to streamline data collection and improve overall trial efficiency. Additionally, the integration of telehealth services into virtual trials allows for continuous patient engagement, further enhancing the flexibility and scalability of clinical research.

The COVID-19 pandemic accelerated the adoption of virtual trials, forcing pharmaceutical companies to adopt remote methodologies to maintain progress in drug development. As the benefits of decentralized trials become more apparent-such as reduced overhead costs, improved data quality, and faster recruitment, many organizations are committing to these models even post-pandemic. This shift is not only changing how trials are conducted but also influencing how CROs design and execute clinical studies, positioning them as essential partners in managing and optimizing the new clinical trial landscape. As DCTs become more commonplace, the demand for CRO services that can manage these trials is expected to increase significantly.

Real-World Evidence (RWE) and Real-World Data (RWD) Integration

Real-World Evidence (RWE) and Real-World Data (RWD) integration is rapidly transforming the global Contract Research Organization (CRO) services market. These data types are derived from sources outside traditional randomized controlled trials, such as electronic health records (EHRs), insurance claims data, patient registries, and mobile health applications. The growing reliance on RWE and RWD reflects a shift towards more comprehensive, patient-centered approaches in clinical research. Pharmaceutical companies and healthcare providers are increasingly utilizing RWE and RWD to enhance the understanding of how drugs perform in real-world settings, which is essential for regulatory submissions, post-market surveillance, and value-based healthcare models.

CROs are playing a crucial role in the integration of RWE and RWD by providing services that capture and analyze these data sources. By incorporating RWD into clinical trials, CROs are helping drug developers evaluate the effectiveness, safety, and long-term outcomes of treatments in broader patient populations. This approach also helps identify treatment patterns, assess the economic impact of therapies, and determine patient subgroups that may benefit the most from certain interventions. Regulatory bodies like the U.S. FDA and EMA are increasingly accepting RWE for drug approval and reimbursement decisions, further propelling its integration into clinical development programs.

CROs with expertise in data analytics, biometrics, and regulatory affairs are essential for leveraging the power of RWE and RWD. As these data sources become more critical to drug development, the demand for CRO services that specialize in RWE and RWD integration is expected to grow. The trend supports more informed decision-making, enhances the quality of clinical trials, and accelerates drug approval processes, making CROs indispensable in the evolving pharmaceutical landscape.

Segmental Insights

Type Insights

In 2023, based on the type, the early phase development services segment is dominating the Global Contract Research Organization (CRO) Services Market. This is attributed to the increasing complexity and high costs associated with early-stage drug development. Early phase services, including chemistry, manufacturing, and controls (CMC), preclinical testing, and discovery services, are essential for pharmaceutical and biotechnology companies aiming to bring new treatments to the market. The early phase is critical because it sets the foundation for the drug development process, determining whether a compound will proceed to clinical trials and ultimately be commercialized.

The demand for these services has risen as pharmaceutical companies face growing pressure to optimize R&D spending while ensuring high-quality results in the early phases of development. Early phase services help mitigate risks by providing essential data on the safety and efficacy of potential drugs before they enter costly and time-consuming clinical trials. CROs are increasingly being called upon to provide comprehensive solutions that integrate various disciplines, including toxicology, pharmacokinetics, and regulatory affairs, to ensure that early-phase research is streamlined and efficient.

Additionally, the growth of biologics and personalized medicine has contributed to the dominance of early-phase services. The complexity of developing biologic drugs and the need for personalized treatments require specialized expertise, which CROs are well-positioned to provide. As the pharmaceutical industry becomes more focused on precision medicine, the demand for advanced early-phase services is expected to continue rising.

Application Insights

Based on the application, the oncology segment is dominating in the Global Contract Research Organization (CRO) Services Market. The increasing prevalence of cancer worldwide has led to a surge in the demand for oncology-specific drug development services.

For instance, as per the World Health Organization (WHO)'s cancer agency, in 2022, the global cancer incidence reached approximately 20 million new cases, with 9.7 million deaths attributed to the disease. The number of individuals surviving at least five years post-diagnosis was estimated at 53.5 million. Statistics indicate that around one in five people will develop cancer in their lifetime, with mortality rates suggesting that approximately one in nine men and one in twelve women will succumb to the disease. These figures highlight the significant and growing impact of cancer globally, driving continued investment in research, treatment innovations, and healthcare solutions aimed at improving survival rates.

As cancer remains one of the leading causes of death globally, pharmaceutical companies are heavily investing in oncology research to develop more effective therapies, including targeted treatments, immunotherapies, and personalized medicine.

CROs play a crucial role in oncology research by providing specialized expertise in conducting clinical trials for oncology drugs, managing complex trial protocols, patient recruitment, and navigating regulatory hurdles. The rise in the number of oncology clinical trials, including early-phase and late-stage studies, has driven the demand for CROs with experience in handling oncology trials. Given the complexity of oncology studies, CROs are increasingly offering integrated services that encompass everything from preclinical studies to post-market surveillance, ensuring that drug development timelines are minimized, and regulatory approval is achieved efficiently.

Regional Insights

In 2023, North America emerged as the dominant region in the Global Contract Research Organization (CRO) Services Market, holding the largest market share. Several factors contributed to North America's strong position in the CRO market. The region's advanced healthcare infrastructure, coupled with a robust pharmaceutical and biotechnology sector, has created a favorable environment for clinical research activities. Major pharmaceutical companies and emerging biotech firms in the U.S. and Canada are increasingly outsourcing research and development services to CROs to streamline operations, reduce costs, and accelerate the time to market for new drugs.

North America's dominance is also fueled by the region's high R&D investments and the growing number of clinical trials conducted by pharmaceutical companies. With large-scale drug development projects, including clinical trials in oncology, neurology, and immunology, CROs are essential in providing specialized expertise and infrastructure. The region's regulatory bodies, such as the FDA, have also fostered a favorable regulatory environment for clinical research, encouraging both local and global companies to base their clinical trials in North America.

Key Market Players

  • Medpace, Inc.
  • Laboratory Corporation of America Holdings
  • ICON plc
  • IQVIA Inc.
  • Syneos Health Inc.
  • Parexel International Corporation
  • Charles River Laboratories International Inc.
  • Thermofisher Scientific Inc.
  • Pharmaron Beijing Co., Ltd.
  • Altasciences

Report Scope:

In this report, the Global Contract Research Organization (CRO) Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Contract Research Organization (CRO) Services Market, By Type:

  • Early Phase Development Services
  • Clinical
  • Laboratory Service
  • Others

Contract Research Organization (CRO) Services Market, By Application:

  • Oncology
  • Neurology
  • Cardiology
  • Infectious Disease
  • Metabolic Disorder
  • Renal/Nephrology
  • Others

Contract Research Organization (CRO) Services Market, By End User:

  • Pharmaceutical & Biotechnological Companies
  • Medical Device Companies
  • Academic & Research Institutes
  • Others

Contract Research Organization (CRO) Services Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Contract Research Organization (CRO) Services Market.

Available Customizations:

Global Contract Research Organization (CRO) Services Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Service Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Contract Research Organization (CRO) Services Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Early Phase Development Services [Chemistry, Manufacturing and Controls (CMC), Preclinical Service, and Discovery], Clinical [Phase 1, Phase 2, Phase 3, and Phase 4], Laboratory Service, and Others)
    • 5.2.2. By Application (Oncology, Neurology, Cardiology, Infectious Disease, Metabolic Disorder, Renal/Nephrology, and Others)
    • 5.2.3. By End User (Pharmaceutical & Biotechnological Companies, Medical Device Companies, Academic & Research Institutes, and Others)
    • 5.2.4. By Company (2023)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America Contract Research Organization (CRO) Services Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Contract Research Organization (CRO) Services Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Mexico Contract Research Organization (CRO) Services Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Canada Contract Research Organization (CRO) Services Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Contract Research Organization (CRO) Services Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Contract Research Organization (CRO) Services Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany Contract Research Organization (CRO) Services Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Contract Research Organization (CRO) Services Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Contract Research Organization (CRO) Services Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Contract Research Organization (CRO) Services Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia-Pacific Contract Research Organization (CRO) Services Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Contract Research Organization (CRO) Services Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Contract Research Organization (CRO) Services Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. South Korea Contract Research Organization (CRO) Services Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. Japan Contract Research Organization (CRO) Services Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Contract Research Organization (CRO) Services Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. South America Contract Research Organization (CRO) Services Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Contract Research Organization (CRO) Services Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Contract Research Organization (CRO) Services Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Contract Research Organization (CRO) Services Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. Middle East and Africa Contract Research Organization (CRO) Services Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Contract Research Organization (CRO) Services Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Contract Research Organization (CRO) Services Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Contract Research Organization (CRO) Services Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Medpace, Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Laboratory Corporation of America Holdings
  • 14.3. ICON plc
  • 14.4. IQVIA Inc.
  • 14.5. Syneos Health Inc.
  • 14.6. Parexel International Corporation
  • 14.7. Charles River Laboratories International Inc.
  • 14.8. Thermofisher Scientific Inc.
  • 14.9. Pharmaron Beijing Co., Ltd.
  • 14.10. Altasciences

15. Strategic Recommendations

16. About Us & Disclaimer